10 research outputs found
Melanin-Concentrating Hormone acts through hypothalamic kappa opioid system and p70S6K to stimulate acute food intake.
Melanin-Concentrating Hormone (MCH) is one of the most relevant orexigenic factors specifically located in the lateral hypothalamic area (LHA), with its physiological relevance demonstrated in studies using several genetically manipulated mice models. However, the central mechanisms controlling MCH-induced hyperphagia remain largely uncharacterized. Here, we show that central injection of MCH in mice deficient for kappa opoid receptor (k-OR) failed to stimulate feeding. To determine the hypothalamic area responsible for this MCH/k-OR interaction, we performed virogenetic studies and found that downregulation of k-OR by adeno-associated viruses (shOprk1-AAV) in LHA, but not in other hypothalamic nuclei, was sufficient to block MCH-induced food intake. Next, we sought to investigate the molecular signaling pathway within the LHA that mediates acute central MCH stimulation of food intake. We found that MCH activates k-OR and that increased levels of phosphorylated extracellular signal regulated kinase (ERK) are associated with downregulation of phospho-S6 Ribosomal Protein. This effect was prevented when a pharmacological inhibitor of k-OR was co-administered with MCH. Finally, the specific activation of the direct upstream regulator of S6 (p70S6K) in the LHA attenuated MCH-stimulated food consumption. Our results reveal that lateral hypothalamic k-OR system modulates the orexigenic action of MCH via the p70S6K/S6 pathway
Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial
Background. Early and intensive treatment is important to inducing remission and preventing joint damage in patients with rheumatoid arthritis. While intensive combination therapy (Disease Modifying Anti-rheumatic Drugs and/or biologicals) is the most effective, rheumatologists in daily clinical practice prefer to start with monotherapy methotrexate and bridging corticosteroids. Intensive treatment should be started as soon as the first symptoms manifest, but at this early stage, ACR criteria may not be fulfilled, and there is a danger of over-treatment. We will therefore determine which induction therapy is most effective in the very early stage of persistent arthritis. To overcome over-treatment and under-treatment, the intensity of induction therapy will be based on a prediction model that predicts patients' propensity for persistent arthritis. Methods. A multicenter stratified randomized single-blind controlled trial is currently being performed in patients 18 years or older with recent-onset arthritis. Eight hundred ten patients are being stratified according to the likelihood of their developing persistent arthritis. In patients with a high probability of persistent arthritis, we will study combination Disease Modifying Antirheumatic Drug therapy compared to monotherapy methotrexate. In patients with an intermediate probability of persistent arthritis, we will study Disease Modifying Antirheumatic Drug of various intensities. In patients with a low probability, we will study non-steroidal anti-inflammatory drugs, hydroxychloroquine and a single dose of corticosteroids. If disease activity is not sufficiently reduced, treatment will be adjusted according to a step-up protocol. If remission is achieved for at least six months, medication will be tapered off. Patients will be followed up every three months over two years. Discussion. This is the first rheumatological study to base treatment in early arthritis on a prediction rule. Treatment will be stratified according to the probability of persistent arthritis, and different combinations of treatment per stratum will be evaluated. Treatment will be started early, and patients will not need to meet the ACR-criteria for rheumatoid arthritis. Trial registration. This trial has been registered in Current Controlled Trials with the ISRCTN26791028
Recombinant adeno-associated virus: efficient transduction of the rat VMH and clearance from blood.
To promote the efficient and safe application of adeno-associated virus (AAV) vectors as a gene transfer tool in the central nervous system (CNS), transduction efficiency and clearance were studied for serotypes commonly used to transfect distinct areas of the brain. As AAV2 was shown to transduce only small volumes in several brain regions, this study compares the transduction efficiency of three AAV pseudotyped vectors, namely AAV2/1, AAV2/5 and AAV2/8, in the ventromedial nucleus of the hypothalamus (VMH). No difference was found between AAV2/1 and AAV2/5 in transduction efficiency. Both AAV2/1 and AAV2/5 achieved a higher transduction rate than AAV2/8. One hour after virus administration to the brain, no viral particles could be traced in blood, indicating that no or negligible numbers of virions crossed the blood-brain barrier. In order to investigate survival of AAV in blood, clearance was determined following systemic AAV administration. The half-life of AAV2/1, AAV2/2, AAV2/5 and AAV2/8 was calculated by determining virus clearance rates from blood after systemic injection. The half-life of AAV2/2 was 4.2 minutes, which was significantly lower than the half-lives of AAV2/1, AAV2/5 and AAV2/8. With a half-life of more than 11 hours, AAV2/8 particles remained detectable in blood significantly longer than AAV2/5. We conclude that application of AAV in the CNS is relatively safe as no AAV particles are detectable in blood after injection into the brain. With a half-life of 1.67 hours of AAV2/5, a systemic injection with 1Ă109 genomic copies of AAV would be fully cleared from blood after 2 days
Comparison of transduction efficiency of serotype AAV2/1, AAV2/5 and AAV2/8 in the VMH.
<p>Rats (nâ=â6) were injected with 1Ă10<sup>9</sup> genomic copies of AAV2/1, AAV2/5 or AAV2/8 in the VMH. The transduced area was identified using ISH on GFP. AAV2/1 and AAV2/5 were equally efficient in transducing the VMH (A, B, D) and performed significantly better than AAV2/8 (C, D) (P<0.01 and P<0.05, respectively). The VMH area is indicated by a dotted line. Figure E depicts the hypothalamic area. The square indicates the area that is enlarged in Figures A, B and C. mt â=â mammillary tract; f â=â fornix; dmh â=â dorsomedial hypothalamus; vmh â=â ventromedial hypothalamus. Scale bar: 500 ”m.</p
Blood clearance kinetics of AAV2/1, AAV2/2, AAV2/5 and AAV2/8 after systemic administration.
<p>Rats (nâ=â6) received a systemic injection of 1Ă10<sup>9</sup> AAV2/1, AAV2/2, AAV2/5 or AAV2/8 and blood samples were collected 10 m, 20 m, 40 m, 1 h, 4 h and 24 h after injection. AAV2/2 showed a significantly faster clearance rate than AAV2/1, AAV2/5 and AAV2/8. Four hours after injection, less than 3% of the starting material of AAV2/1 and AAV2/2 could be traced. AAV2/8 showed a delayed clearance rate. One day after injection still more than 20% of the starting material was present in the circulation.</p
Melanin-concentrating hormone acts through hypothalamic kappa opioid system and p70S6K to stimulate acute food intake
Melanin-Concentrating Hormone (MCH) is one of the most relevant orexigenic factors specifically located in the lateral hypothalamic area (LHA), with its physiological relevance demonstrated in studies using several genetically manipulated mice models. However, the central mechanisms controlling MCH-induced hyperphagia remain largely uncharacterized. Here, we show that central injection of MCH in mice deficient for kappa opoid receptor (k-OR) failed to stimulate feeding. To determine the hypothalamic area responsible for this MCH/k-OR interaction, we performed virogenetic studies and found that downregulation of k-OR by adeno-associated viruses (shOprk1-AAV) in LHA, but not in other hypothalamic nuclei, was sufficient to block MCH-induced food intake. Next, we sought to investigate the molecular signaling pathway within the LHA that mediates acute central MCH stimulation of food intake. We found that MCH activates k-OR and that increased levels of phosphorylated extracellular signal regulated kinase (ERK) are associated with downregulation of phospho-S6 Ribosomal Protein. This effect was prevented when a pharmacological inhibitor of k-OR was co-administered with MCH. Finally, the specific activation of the direct upstream regulator of S6 (p70S6K) in the LHA attenuated MCH-stimulated food consumption. Our results reveal that lateral hypothalamic k-OR system modulates the orexigenic action of MCH via the p70S6K/S6 pathway.This work has been supported by grants from Ministerio de Economia y Competitividad (CD: BFU2014-55871; RN: BFU2015-70664-R; ML: SAF2015-71026-R), Xunta de Galicia (ML: 2015-
CP079; RN: 2015-CP080 and PIE13/00024); Fundacion SEEN (RN); Helse Vest RHF (JF); FundaciĂłn AstraZeneca (RN: 2016-PO031); Centro de Investigacion BiomĂ©dica en Red (CIBER) de FisiopatologĂa de la Obesidad y Nutricion (CIBERobn). CIBERobn is an initiative of the Instituto de Salud Carlos III (ISCIII) of Spain which is supported by FEDER funds. The research leading to these results has also received funding from the European Community's Seventh Framework Programme under the following grant: RN: ERC StG28140
Recommended from our members
Hypothalamic kappa opioid receptor mediates both dietâinduced and melanin concentrating hormoneâinduced liver damage through inflammation and endoplasmic reticulum stress
The opioid system is widely known to modulate the brain reward system and thus affect the behavior of humans and other animals, including feeding. We hypothesized that the hypothalamic opioid system might also control energy metabolism in peripheral tissues. Mice lacking the kappa opioid receptor (ÎșOR) and adenoviral vectors overexpressing or silencing ÎșOR were stereotaxically delivered in the lateral hypothalamic area (LHA) of rats. Vagal denervation was performed to assess its effect on liver metabolism. Endoplasmic reticulum (ER) stress was inhibited by pharmacological (tauroursodeoxycholic acid) and genetic (overexpression of the chaperone glucoseâregulated protein 78 kDa) approaches. The peripheral effects on lipid metabolism were assessed by histological techniques and western blot. We show that in the LHA ÎșOR directly controls hepatic lipid metabolism through the parasympathetic nervous system, independent of changes in food intake and body weight. ÎșOR colocalizes with melanin concentrating hormone receptor 1 (MCHâR1) in the LHA, and genetic disruption of ÎșOR reduced melanin concentrating hormoneâinduced liver steatosis. The functional relevance of these findings was given by the fact that silencing of ÎșOR in the LHA attenuated both methionine cholineâdeficient, dietâinduced and cholineâdeficient, highâfat dietâinduced ER stress, inflammation, steatohepatitis, and fibrosis, whereas overexpression of ÎșOR in this area promoted liver steatosis. Overexpression of glucoseâregulated protein 78 kDa in the liver abolished hypothalamic ÎșORâinduced steatosis by reducing hepatic ER stress. Conclusions:: This study reveals a novel hypothalamicâparasympathetic circuit modulating hepatic function through inflammation and ER stress independent of changes in food intake or body weight; these findings might have implications for the clinical use of opioid receptor antagonists. (Hepatology 2016;64:1086â1104
Hypothalamic kappa opioid receptor mediates both diet- and MCH-induced liver damage through inflammation and ER stress
The opioid system is widely known to modulate the brain reward system and thus affect human and animal behaviour, including feeding. We hypothesized that the hypothalamic opioid system might also control energy metabolism in peripheral tissues. Mice lacking the kappa opioid receptor (ÎșOR) and adenoviral vectors over-expressing or silencing ÎșOR were stereotaxically delivered in the lateral hypothalamic area (LHA) of rats. Vagal denervation was performed to assess its effect on liver metabolism. ER stress was inhibited by pharmacological (tauroursodeoxycholic acid - TUDCA) and genetic (over-expression of the chaperone glucose-regulated protein 78 kDa - GRP78) approaches. The peripheral effects on lipid metabolism were assessed by histological techniques and Western blot. We show that in the LHA, ÎșOR directly controls hepatic lipid metabolism via the parasympathetic nervous system, independent of changes in food intake and body weight. ÎșOR colocalizes with melanin concentrating hormone receptor (MCH-R1) in the LHA and genetic disruption of ÎșOR reduced MCH-induced liver steatosis. The functional relevance of these findings was given by the fact that silencing of ÎșOR in the LHA attenuated both methionine choline-deficient diet- and choline deficient-high fat diet-induced ER stress, inflammation, steatohepatitis and fibrosis, whereas over-expression of ÎșOR in this area promoted liver steatosis. Over-expression of the GRP78 in the liver abolished hypothalamic ÎșOR-induced steatosis by reducing hepatic ER stress. CONCLUSIONS: Overall, this study reveals a novel hypothalamic-parasympathetic circuit modulating hepatic function via inflammation and ER stress independent of changes in food intake or body weight. These findings might have implications for the clinical use of opioid receptor antagonists. This article is protected by copyright. All rights reserved
Recombinant Adeno-Associated Virus: Efficient Transduction of the Rat VMH and Clearance from Blood
Hypothalamic Îș-Opioid Receptor Modulates the Orexigenic Effect of Ghrelin
The opioid system is well recognized as an important regulator of appetite and energy balance. We now hypothesized that the hypothalamic opioid system might modulate the orexigenic effect of ghrelin. Using pharmacological and gene silencing approaches, we demonstrate that ghrelin utilizes a hypothalamic Îș-opioid receptor (KOR) pathway to increase food intake in rats. Pharmacological blockade of KOR decreases the acute orexigenic effect of ghrelin. Inhibition of KOR expression in the hypothalamic arcuate nucleus is sufficient to blunt ghrelin-induced food intake. By contrast, the specific inhibition of KOR expression in the ventral tegmental area does not affect central ghrelin-induced feeding. This new pathway is independent of ghrelin-induced AMP-activated protein kinase activation, but modulates the levels of the transcription factors and orexigenic neuropeptides triggered by ghrelin to finally stimulate feeding. Our novel data implicate hypothalamic KOR signaling in the orexigenic action of ghrelin